Annual Review
Adopting innovative therapies for benign prostatic hyperplasia
— Case study

Adopting innovative therapies for benign prostatic hyperplasia

The South West AHSN has actively engaged with urology departments across the region to support NHS trusts to adopt innovative treatments to tackle benign prostatic hyperplasia (BPH).

In 2022/23 a suite of four NICE-recommended products to treat BPH were launched on NHS England’s MedTech Funding Mandate, to accelerate the uptake of these treatments so that patients benefit from them more quickly.   

The South West AHSN has actively engaged with clinicians and commissioners in urology departments at local trusts to raise awareness of these technologies and support adoption. 
Man with urology problem visiting doctor at hospital
  • Across the South West we have seen good levels of uptake and interest in the products, meaning patients are benefitting from a wider range of treatment options. 
  • All the products can be performed as a day case. Not only does this provide patients with an improved experience from a quicker recovery, but it also frees up valuable hospital beds, allowing more operations to be completed in one day.  
  • Waiting lists in urology departments are high following the COVID-19 pandemic. By providing faster treatment options, urology departments are able to reduce backlog. 

Website Links

Open in new window